- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01612299
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation patients. B. To investigate progression of CAC in patients undergoing renal transplantation within the study period.
Secondary objectives:
- To evaluate in renal transplantation the effect of Zortress® versus standard immunosuppression therapy on bone mass as evidenced by changes in quantitative computed tomography (QCT) and dual energy X-ray absorptiometry (DXA).
- To evaluate in renal transplantation the effect of Zortress® versus standard immunosuppression therapy on activity of bone forming and resorbing cells as evidenced by changes in bone histology.
- To evaluate in renal transplantation the effect of Zortress® versus standard immunosuppression therapy on biochemical parameters of bone turnover as evidenced by changes in serum Parathyroid Hormone (PTH), Bone-Specific Alkaline Phosphatase (BSAP), Tartrate-Resistant Acid Phosphatase (TRAP), Sclerostin, Receptor Activator of Nuclear factor Kappa B Ligand (RANKL), Osteoprotegerin (OPG), , serum CTX (C-terminal telopeptide of type 1 collagen), and urinary NTX (N-terminal cross link telopeptide).
- To evaluate in renal transplantation the effect of Zortress® versus standard immunosuppression therapy on cardiovascular events, graft rejection and patient survival.
Study Overview
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- De novo renal transplant recipients (from deceased or living donors) between 18-70 years of age
- Willingness to participate in the study and comply with study requirements as evidenced by signed IRB-approved informed consent
Enrollment Exclusion Criteria:
- Previous solid organ transplant
- Known hypersensitivity to any of the study drugs, or their class, or to any of their excipients
- Recipients of an investigational drug within 30 days before transplant
- Any abnormal physical or laboratory findings of clinical significance which would interfere with conduct of the study
- Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, or unwilling to use medically approved means of contraception
Randomization Exclusion Criteria:
- Platelet count <75,000/mm
- White blood cell count of < 2,000/mm³
- Hypercholesterolemia (>400 mg/dL) or hypertriglyceridemia (>500 mg/dL) despite lipid-lowering therapy
- Presence of any clinically significant infection requiring IV antibiotics
- Positive serum HCG (women of childbearing potential)
- Spot urine protein to creatinine ratio (UPr/Cr ) ≥ 0.5
- Any biopsy-confirmed acute rejection since transplant
- Baseline CAC score < 100 at baseline reading
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard Immunosuppression
Tacrolimus + Myfortic®/Cellcept + Corticosteroids
|
Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12. Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml. |
Experimental: Zortress®
Tacrolimus + Zortress® + Corticosteroids
|
Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12. Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression of Coronary Artery Calcification
Time Frame: 1 year
|
The primary outcome of this study is the proportion of pts in the treatment group who experience a 1yr increase of ≥2.5 for the square-root transformed volume indicating CAC progression.
Student's Fisher's Exact T-tests will be used to determine progression of CAC score between control & treatment groups.
Secondary objectives 1-3 examine 1yr changes in several measurement outcome variables.
Fisher's exact tests & confidence intervals for the difference in proportions will be used to compare the two groups in terms of cardiovascular events, graft rejection, & pt survival.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3048108907
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplant
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
Queen Mary University of LondonRecruitingImmunosuppression | Renal Transplant Rejection | Renal Transplant Failure | Renal Transplant InfectionUnited Kingdom
-
PfizerCompletedRenal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft RecipientsUnited States, Australia, Germany, Italy, Spain, Brazil, Argentina
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Alp SenerNot yet recruitingRenal Transplant | Kidney Transplant
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
National Institute of Allergy and Infectious Diseases...University of PittsburghRecruitingKidney Transplant | Renal Transplant RecipientsUnited States
-
Liverpool University Hospitals NHS Foundation TrustKidney Research United KingdomNot yet recruitingFrailty | Kidney Transplant Rejection | Renal Transplant | Diagnosis | Kidney Transplant; Complications | Kidney Transplant | Renal Transplant Failure | Transplant DysfunctionUnited Kingdom
-
University of AarhusCompletedRenal Transplant Candidate for Right Kidney | Renal Transplant Candidate for Left KidneyDenmark
-
Jeffrey Veale, MDOneLegacy FoundationRecruitingTolerance | Renal Transplant Rejection | Kidney TransplantUnited States
Clinical Trials on Zortress® /Everolimus
-
Dana-Farber Cancer InstituteNovartis PharmaceuticalsCompletedTuberous Sclerosis Complex | TSC1 | TSC2 | MTORUnited States
-
Washington University School of MedicineTyrogenexTerminatedAdenocarcinoma | Pancreatic NeoplasmsUnited States
-
University of Toledo Health Science CampusNovartis PharmaceuticalsCompleted
-
University of California, San FranciscoNovartis; amfAR, The Foundation for AIDS ResearchCompletedHIV | Liver Transplant | Kidney TransplantUnited States
-
Novartis PharmaceuticalsCompleted
-
amy tierstenNovartisActive, not recruiting
-
Azienda Ospedaliera di PadovaUnknownLiver Diseases | Liver Failure | Liver Cirrhosis | Liver NeoplasmsItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); NovartisCompleted
-
M.D. Anderson Cancer CenterNovartis Pharmaceuticals; BTG International Inc.Withdrawn
-
National Cancer Institute (NCI)CompletedGlioblastoma | Brain Tumor | Anaplastic GliomaUnited States